Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Equity Ratio (2021 - 2025)

Krystal Biotech's Equity Ratio history spans 5 years, with the latest figure at 0.91 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 2.01% year-over-year to 0.91; the TTM value through Dec 2025 reached 0.91, up 2.01%, while the annual FY2025 figure was 0.91, 2.01% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.91 at Krystal Biotech, roughly flat from 0.92 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.97 in Q1 2021 and bottomed at 0.89 in Q1 2022.
  • The 5-year median for Equity Ratio is 0.93 (2022), against an average of 0.93.
  • The largest YoY upside for Equity Ratio was 3.67% in 2022 against a maximum downside of 8.52% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.95 in 2021, then decreased by 1.33% to 0.94 in 2022, then rose by 1.75% to 0.95 in 2023, then dropped by 5.8% to 0.9 in 2024, then rose by 2.01% to 0.91 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Equity Ratio are 0.91 (Q4 2025), 0.92 (Q3 2025), and 0.91 (Q2 2025).